CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 111 enrolled
Drug / intervention
TRC105 and Pazopanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01975519
NCT01975519Phase 2Completed
CompareCT.gov

A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

Tracon Pharmaceuticals Inc.·interventional·Posted Nov 4, 2013·Updated May 20, 2020

In Brief

A Phase 2 clinical trial evaluating TRC105 and Pazopanib for Advanced Soft Tissue Sarcoma. Completed, enrolled 111 participants across 9 sites.

Detailed Summary

The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose pazopanib in patients with advanced soft tissue sarcoma. Up to 30 patients will be treated. The purpose of the phase 2 portion is to estimate the PFS of patients with advanced soft tissue sarcoma by RECIST 1.1 and estimate ORR in a separate cohort of patients with angiosarcoma by RECIST 1.1. Up to 89 patients will be treated in phase 2, including two cohorts of up to 13 patients with angiosarcoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Soft Tissue Sarcoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 4, 2013
Enrollment StartDec 10, 2013
Primary CompletionMar 11, 2019
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 12.7 years ago

Interventions

TRC105 and Pazopanibdrug

Weekly TRC105 in combination with standard dose Pazopanib.